Highest-materiality recent filing
Medifast appoints Nicholas Johnson as CEO; Dan Chard becomes non-executive Chairman
Nicholas Johnson, 46, becomes CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.
Medifast Q1 revenue $76M, down 34% YoY; net loss $2.1M; guides Q2 revenue $60-80M
Revenue fell 34.3% to $76.0M; net loss widened to $2.1M ($0.19 EPS) from $0.8M loss.
Medifast (MED) entered a Cooperation Agreement with Steamboat Capital Partners (beneficial owner >5%) on March 19, 2026.
Medifast Q4 revenue falls 37% to $75.1M; net loss $18.1M, guides FY26 rev $270-300M
Revenue $75.1M, down 36.9% YoY; active earning coaches down 40.6% to 16,100.
Medifast Q3 revenue down 36% to $89.4M; net loss $2.3M; coaches drop 35%
Revenue $89.4M vs $140.2M YoY; net loss $0.21 per diluted share vs $0.10 income.
Medifast Q2 revenue falls 37.4% to $105.6M; active coaches down 33%; Q3 guidance weak
Revenue $105.6M, down 37.4% YoY; active OPTA VIA coaches 22,800 (-32.7% YoY); diluted EPS $0.22 (includes $2.0M net LifeMD gain).
Medifast Q1 2025: revenue down 34% to $115.7M, net loss $0.8M; Q2 guidance weak
Revenue fell 33.8% to $115.7M; active earning coaches down 32.8% to 25,400.
Medifast Q4 revenue down 38% to $119M; EPS $0.07; guides Q1 loss
Q4 revenue $119M (-37.7% YoY); active earning coaches 27,100 (-34.1% YoY).
Medifast Q3 2024 revenue down 40.6% to $140.2M; EPS $0.10; guides Q4 revenue $100-120M
Revenue $140.2M, down 40.6% YoY; net income $1.1M ($0.10 diluted EPS); adjusted EPS $0.35.
Medifast Q2 revenue falls 43% to $168.6M; net loss $0.75/share, guides Q3 loss
Revenue $168.6M, down 43.1% YoY; active earning Coaches 33,900 (-36.2%); avg revenue per Coach $4,972 (-10.9%).
Medifast posts 50% revenue decline to $174.7M in Q1; EPS $0.76 vs $3.67 YoY
Revenue of $174.7M, down 49.9% YoY; net income $8.3M ($0.76 diluted EPS) vs $40.0M ($3.67) in Q1 2023.
Medifast Q4 revenue falls 43% to $191M; guides Q1 2024 revenue $155-175M
Q4 net income $6.0M ($0.55 diluted EPS); adjusted net income $11.9M ($1.09 adjusted EPS).
Medifast commits $20M to LifeMD ($10M platform contributions, $10M stock purchase) for collaboration.
Medifast Q3 revenue down 39.6% YoY to $235.9M; EPS $2.12 vs $3.27
Revenue $235.9M (-39.6% YoY); net income $23.1M (-36.2% YoY); diluted EPS $2.12 vs $3.27.
Medifast Q2 revenue falls 34.7% to $296.2M; diluted EPS $2.77 vs $3.42
Revenue $296.2M (-34.7%); net income $30.3M, EPS $2.77 vs $39.1M, $3.42 prior.
Medifast Q1 revenue down 16.4% to $349M; guides Q2 revenue $250-270M, EPS $1.32-1.44
Revenue $349M (-16.4% YoY); net income $40M ($3.67 diluted EPS) vs $41.8M ($3.59) prior year.
Medifast Q4 revenue down 10.7% to $337.2M; guides Q1 revenue $300-320M
Q4 GAAP EPS $2.41, adjusted EPS $3.70; net income $26.5M vs $34.0M YoY.
Medifast Q3 revenue down 5.6%; cuts FY2022 revenue and EPS guidance on macro headwinds
Revenue $390.4M (-5.6% YoY); net income $36.2M ($3.27 diluted EPS). Non-GAAP adjusted EPS $3.32.
Revenue $453.3M (+15% YoY); net income $39.1M (-16.7%); adjusted EPS $3.87 (-2.5%).
Medifast declares $1.64 quarterly dividend, reelects directors, and amends executive severance plan
Stockholders elected seven directors to Medifast's board, each receiving over 8.8 million votes for.
Medifast launches $100M accelerated share repurchase program
Entered ASR with JPMorgan to repurchase $100M of common stock.
Medifast Q1 revenue up 22.6% to $417.6M; raises FY22 guidance
Net income $41.8M ($3.59 diluted EPS) vs $41.1M ($3.46) YoY.
Medifast Q4 revenue $377.8M (+42.6%); FY 2021 revenue $1.526B (+63.2%)
Q4 diluted EPS $2.91 vs $2.36 YoY; net income $34.0M (+21.5%).
Medifast Q3 revenue jumps 52% to $413M; EPS $3.56; coaches up 45%
Revenue increased 52.3% to $413.4M; net income $42.0M, diluted EPS $3.56 (up 22.3%).
Medifast Q2 2021 revenue $394.2M (+79% YoY), EPS $3.96; FY guidance $1.425-1.525B
Revenue $394.2M, up 79.2% YoY; net income $47M (+114.1%); diluted EPS $3.96 (+112.9%).
Effective as of May 29, 2026, Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc. (the “Company”), tendered his resignation from the Company.
On May 20, 2026, the Board appointed Nicholas Johnson, age 46, to serve as Chief Executive Officer of the Company, effective June 1, 2026.
On March 13, 2023, Lauren Walker, Executive Vice President, Supply Chain of Medifast, Inc. (the "Company") informed the Company of her intention to retire, effective May 4, 2023.
Effective as of September 13, 2021, the Board of Directors of Medifast, Inc. (the “Company”) appointed Jonathan B. MacKenzie to serve as Chief Accounting Officer of the Company.
Mr. MacKenzie succeeds James P. Maloney, who will cease to serve as the Company’s Interim Chief Accounting Officer upon the effectiveness of Mr. MacKenzie’s employment.
reported the departure of Stephen K. Johnson, the Company’s Chief Accounting Officer, effective August 5, 2021.
James P. Maloney, the Company’s Chief Financial Officer, will serve as interim principal accounting officer as of the effective date of Mr. Johnson’s resignation.
On August 5, 2021, Medifast, Inc. (the “Company”) and Stephen K. Johnson, the Company’s Chief Accounting Officer, agreed that Mr. Johnson will depart from his position as Chief Accounting Officer and all other positions that he holds as an officer or employee of the Company, effective August 5, 2021.
Max materiality 0.90 · Median 0.75 · Most common event earnings